NuVasive, Inc.

338 articles with NuVasive, Inc.

• NuVasive To Feature Lateral Single-Position Surgery And Surgical Intelligence At Spine Summit 2019

  3/6/2019

  Company sponsors Spine Summit 2019 - 35th Annual Meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves

• NuVasive To Participate In Cowen And Company 39th Annual Health Care Conference

  3/5/2019

  NuVasive, Inc. announced that NuVasive management will present at the Cowen and Company 39th Annual Health Care Conference at The Boston Marriott Copley Place in Boston on Tuesday, March 12, 2019, at 9:20 a.m. ET / 6:20 a.m. PT.

• NuVasive To Present At 8th Annual Leerink Partners Global Healthcare Conference

  2/21/2019

  NuVasive, Inc. announced that NuVasive management will present at the 8th Annual Leerink Partners Global Healthcare Conference at the Lotte New York Palace Hotel in New York City on Thursday, Feb. 28, 2019 at 9 a.m. ET / 6 a.m. PT.

• NuVasive Reports Fourth Quarter And Full Year 2018 Financial Results

  2/20/2019

  Company provides 2019 financial performance guidance

• NuVasive's Proprietary Magnetic Implant System To Be Used In First-Of-Its-Kind, All-Internal Bone Transport System

  2/19/2019

  Company receives FDA 510(k) clearance and CE mark approval for use of minimally invasive Precice® Bone Transport System to treat segmental bone defects up to 10 centimeters in the tibia and femur

• NuVasive Announces Conference Call And Webcast Of Fourth Quarter And Full Year 2018 Results

  1/29/2019

  NuVasive, Inc. announced the Company will release its fourth quarter and full year 2018 earnings results on Wednesday, Feb. 20, 2019 after the close of the market.

• NuVasive Announces Preliminary Unaudited Fourth Quarter And Full Year 2018 Revenue Results

  1/7/2019

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced preliminary unaudited revenue results for the fourth quarter and full year 2018.

• NuVasive CEO J. Christopher Barry Announces New Organizational Structure And Leadership Team

  1/3/2019

  Barry joined NuVasive as CEO on November 5, 2018.

• NuVasive To Participate In 37th Annual J.P. Morgan Healthcare Conference

  12/27/2018

  NuVasive, Inc. announced that NuVasive management will present at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Monday, Jan. 7, 2019, at 3:30 p.m. PT / 6:30 p.m. ET

• NuVasive Grows Cervical Spinal Interbody Portfolio With PEEK Corpectomy Implant

  12/10/2018

  Company receives FDA 510(k) clearance for expanded use of Monolith® Corpectomy System, introducing fully modular PEEK implant indicated for use in the cervical spine

• NuVasive To Participate In The 30th Annual Piper Jaffray Healthcare Conference

  11/19/2018

  NuVasive, Inc. announced today that NuVasive management will be presenting at the Piper Jaffray 30th Annual Healthcare Conference at the Lotte New York Palace in New York City on Thursday, November 29, 2018 at 9:30 a.m. ET / 6:30 a.m. PT.

• NuVasive Launches First-Of-Its-Kind Brigade® Lateral Implant And Instrumentation Optimized For Lateral Anterior Lumbar Interbody Fusion Spine Surgery

  11/15/2018

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the U.S. commercial launch of Brigade® Lateral, the industry's first interbody implant and instrumentation optimized for lateral anterior lumbar interbody fusion (ALIF) spine surgery.

• NuVasive's Proprietary Porous PEEK™ Implant To Be Used In Flagship XLIF® Procedure

  11/8/2018

  Company receives FDA 510(k) clearance for use of COHERE® interbody in XLIF® procedure as new clinical study further validates important benefits of Porous PEEK™ material technology

• NuVasive Reports Third Quarter 2018 Financial Results

  10/30/2018

  NuVasive, Inc. today announced financial results for the quarter ended September 30, 2018. 

• NuVasive Names J. Christopher Barry To Succeed Gregory T. Lucier As Chief Executive Officer; Lucier To Remain Chairman Of The Board

  10/19/2018

  NuVasive, Inc. today announced its Board of Directors has named J. Christopher Barry to succeed Gregory T. Lucier as chief executive officer (CEO) effective November 5, 2018.

• NuVasive Announces Conference Call And Webcast Of Third Quarter 2018 Results

  10/11/2018

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will release its third quarter 2018 earnings results on Tuesday, October 30, 2018 after the close of the market.

• NuVasive Announces Strategic Partnership With Biedermann Technologies To Access Intellectual Property And Co-Develop State-of-the-Art Complex Spine Solutions

  10/9/2018

  Biedermann Technologies' leading innovations to be available with NuVasive's RELINE® posterior fixation system to create differentiated adult and pediatric technology solutions

• NuVasive Clinical Services Awarded Sole Source Intraoperative Neuromonitoring Services Contract With Premier

  10/8/2018

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive Clinical Services has been awarded a three-year, sole source supplier contract for Intraoperative Neuromonitoring (IONM) Services with Premier.

• NuVasive To Showcase Comprehensive Solutions For Complex Spinal Deformities At Scoliosis Research Society Annual Meeting

  10/4/2018

  NuVasive, Inc. (NASDAQ: NUVA), focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will highlight several of its latest spinal innovations to treat complex spinal deformities at the Scoliosis Research Society (SRS) Annual Meeting held October 10-13, 2018

• NuVasive Expands Biologics Portfolio To Meet Clinical And Economic Needs

  9/24/2018

  This portfolio expansion demonstrates the Company's strategic efforts to deliver the most differentiated biologics portfolio in the spine industry.